Complement activation by HIV-1-infected target cells enhances IL-2-stimulated but not unstimulated ADCC activity mediated by peripheral blood mononuclear cells. NLM AIDSLINE Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Complement activation by HIV-1-infected target cells enhances IL-2-stimulated but not unstimulated ADCC activity mediated by peripheral blood mononuclear cells.

Clin Immunol Immunopathol. 1996 Jan;78(1):77-82. Unique Identifier : AIDSLINE MED/96173873
Sereti I; Spear GT; Department of Immunology/Microbiology, Rush Medical School,; Chicago, Illinois 60612, USA.

Abstract: The goal of this study was to determine whether deposition of complement C3 breakdown products on the surface of HIV-infected target cells could augment the levels of antibody-dependent cellular cytotoxicity (ADCC) mediated by peripheral blood mononuclear cells (PBMC). Although C3 was deposited on the surface of infected cells in the presence of anti-HIV antibody from infected persons, no increase in the levels of ADCC mediated by freshly isolated PBMC was seen with either infected H9 or CEM-NKr target cells. However, a significant increase in ADCC was observed due to deposition of C3 on target cells with IL-2-stimulated effector cells. These results show that C3 deposition on target cells can increase ADCC cytotoxicity under certain conditions. Complement may thus contribute to destruction of HIV-infected cells through this mechanism in vivo, although these experiments suggest that specific antibody is the major targeting molecule for ADCC.
Keywords: *Antibody-Dependent Cell Cytotoxicity/DRUG EFFECTS Cell Line Complement Activation/DRUG EFFECTS/*PHYSIOLOGY Cytotoxicity Tests, Immunologic Human HIV Infections/*IMMUNOLOGY HIV-1/*IMMUNOLOGY Interleukin-2/*PHARMACOLOGY Leukocytes, Mononuclear/DRUG EFFECTS/*METABOLISM/*VIROLOGY *Lymphocyte Transformation JOURNAL ARTICLEKWDantibody-dependentcellcytotoxicity/drugeffectscelllinecomplementactivation/drugeffects/KWDphysiologycytotoxicitytests,immunologichumanhivinfections/KWDimmunologyhiv-1/KWDimmunologyinterleukin-2/KWDpharmacologyleukocytes,mononuclear/drugeffects/KWDmetabolism/KWDvirologyKWDlymphocytetransformationjournalarticle
960730
M9670509

Copyright © 1996 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .